College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan.
Medicine (Baltimore). 2021 Apr 30;100(17):e25613. doi: 10.1097/MD.0000000000025613.
Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of kidney failure in developed countries. Clinically, DN is usually treated by controlling blood sugar and blood pressure. According to reports, the application of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist can only target a certain stage of disease development. However, the application of Suoquan Pill (SQP) in traditional Chinese medicine has produced obvious clinical effects and minor side effects. It is used to treat DN and other diseases, but there is no systematic review of SQP in the treatment of diabetic nephropathy. This article reviews the effectiveness and safety of SQP in the treatment of DN.
The database sets the registration date for randomized controlled trials (RCT) to March 25, 2021. By searching the following eight Chinese and English electronic databases: Cochrane Library, Embase, PubMed, Science Net, China National Knowledge Infrastructure, China Biomedical Literature Database. Chinese scientific journal database and Wanfang database for analysis. The main results are clinical efficacy, urinary albumin excretion rate, symptom score and quality of life. Finally, Stata 15 was used for meta-analysis.
This study will provide the latest evidence for SQP in the treatment of DN in the following aspects: clinical efficacy, urinary albumin excretion rate, quality of life, symptom score.
The results of this study will provide evidence for evaluating the effectiveness of SQP in the treatment of DN.
10.17605/OSF.IO/KZ9RA.
糖尿病肾病（DN）是糖尿病最常见的并发症之一，也是发达国家肾衰竭的主要原因。临床上，DN 通常通过控制血糖和血压来治疗。据报道，血管紧张素转换酶抑制剂（ACEI）或血管紧张素受体拮抗剂的应用只能针对疾病发展的某个阶段。然而，中药缩泉丸（SQP）的应用在治疗 DN 等疾病方面已产生明显的临床效果，且副作用较小。它被用于治疗 DN 及其他疾病，但尚无 SQP 治疗糖尿病肾病的系统评价。本文综述了 SQP 治疗 DN 的疗效和安全性。
该数据库将随机对照试验（RCT）的注册日期设置为 2021 年 3 月 25 日。通过检索以下 8 个中英文电子数据库：Cochrane 图书馆、Embase、PubMed、Science Net、中国国家知识基础设施、中国生物医学文献数据库、中国科学期刊数据库和万方数据库进行分析。主要结果为临床疗效、尿白蛋白排泄率、症状评分和生活质量。最后，使用 Stata 15 进行荟萃分析。
本研究将在以下方面为 SQP 治疗 DN 提供最新证据：临床疗效、尿白蛋白排泄率、生活质量、症状评分。
本研究结果将为评估 SQP 治疗 DN 的有效性提供证据。
OSF 注册号：10.17605/OSF.IO/KZ9RA。
